Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

News: This New Covid Vaccine Could Bring... (The New York Times) - Behind the headlines

In the news

Media coverage of health and science topics

The New York Times May 5, 2021

This New Covid Vaccine Could Bring Hope to the Unvaccinated World

by Carl Zimmer

The German company CureVac hopes its RNA vaccine will rival those made by Moderna and Pfizer-BioNTech. It could be ready next month.

Read more at The New York Times

Behind the headlines

Research findings and data from the National Library of Medicine

PubMed articles

Vaccine FEBRUARY 22, 2021

Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial

C Aldrich et al

Two 1 μg or 2 μg doses of CV7202 were well tolerated and elicited rabies neutralizing antibody responses that met WHO criteria in all recipients, but 5 μg had unacceptabl …

Related content

Similar articles

Reviews

People also viewed

Also of interest

Additional recent and related news

The Scientist APRIL 7, 2020

Track COVID-19 Vaccines Advancing Through Clinical Trials

Find the latest updates in this one-stop resource, including efficacy data and side effects of approved shots, as well as progress on new candidates entering human studies.

The Scientist NOVEMBER 25, 2020

The Promise of mRNA Vaccines

Long before Moderna’s and Pfizer's COVID-19 shots, scientists had been considering the use of genetically encoded vaccines in the fight against infectious diseases, cancer, and more.

NIH Research Matters MARCH 30, 2021

Measles vaccine used as base for experimental COVID vaccine

Scientists developed a SARS-CoV-2 vaccine by adding a key coronavirus gene to the measles vaccine.

WIRED NOVEMBER 10, 2020

Why It’s a Big Deal If the First Covid Vaccine Is ‘Genetic’

If approved by the FDA, Pfizer and BioNTech’s mRNA vaccine would be the first of its kind, setting a record for speed—but raising questions about distribution.

NIH News Releases JULY 14, 2020

Experimental COVID-19 vaccine safe, generates immune response

NIH-sponsored Phase 1 trial tested mRNA vaccine.